CAR-T & Innovative Therapy Access

China leads the world in approved CAR-T therapies (7 products, 850+ clinical trials) — at 1/3 to 1/5 of US costs. We provide direct access to these life-saving treatments. Our service covers: eligibility screening and biomarker testing coordination, matching with the most appropriate CAR-T center (Shanghai, Beijing, Guangzhou, Tianjin), cost breakdown with insurance and compassionate-use options, apheresis-to-infusion timeline management, and post-CAR-T monitoring support. Beyond CAR-T, we also navigate access to proton/heavy ion therapy (Shanghai Proton Center: 92.9% 5-year NPC survival), Claudin18.2 targeted therapy, TIL therapy, and domestically-developed innovative drugs (Ivosidenib, etc.) available exclusively through China's Boao Lecheng Pilot Zone's "early-access" policy.